Actively Recruiting
Effectiveness and Safety of Pembrolizumab Plus Lenvatinib in Adults With Metastatic Non-Small Cell Lung Cancer With RET Gene Rearrangement
Led by EuroCityClinic LLC · Updated on 2026-09-09
15
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness, safety, and tolerability of pembrolizumab combined with lenvatinib in adults with metastatic non-small cell lung cancer NSCLC who have a confirmed RET gene rearrangement. This study focuses on patients whose disease has progressed after one or more prior systemic treatments. It is a Phase 3, single-center, non-randomized, interventional trial sponsored by EuroCityClinic LLC. Participants will receive pembrolizumab through an intravenous infusion every 3 weeks alongside daily oral lenvatinib. Treatment continues until the disease worsens, unacceptable side effects occur, or treatment is stopped. Tumor response will be evaluated by imaging using RECIST 1.1 criteria, and the study will also analyze clinical tumor features, RET gene variants, and diagnostic methods confirming RET-positive status. During the study, participants will undergo regular monitoring for treatment-related side effects, tumor progression, and overall survival outcomes. Progression-free survival, objective response rate, and disease control rate will be assessed over up to 48 months. Blood tests and imaging studies will be used to evaluate health and response. Participants are expected to remain in the study until disease progression or discontinuation, contributing valuable data on treatment effects and safety.
CONDITIONS
Brief Title
A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation
Research Team
S
Sergey Orlov, Doctor of Medical Sciences, Pr
M
Maria Sviridenko, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here